Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imaging in ocular toxoplasmosis.
Lavinsky D, Romano A, Muccioli C, Belfort R Jr. Lavinsky D, et al. Int Ophthalmol Clin. 2012 Fall;52(4):131-43. doi: 10.1097/IIO.0b013e318265fd78. Int Ophthalmol Clin. 2012. PMID: 22954935 Review. No abstract available.
Fundus autofluorescence of choroidal nevus and melanoma.
Lavinsky D, Belfort RN, Navajas E, Torres V, Martins MC, Belfort R Jr. Lavinsky D, et al. Br J Ophthalmol. 2007 Oct;91(10):1299-302. doi: 10.1136/bjo.2007.116665. Epub 2007 Apr 12. Br J Ophthalmol. 2007. PMID: 17431017 Free PMC article.
Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis.
Paganelli F, Cardillo JA, Dare AR, Melo LA Jr, Lucena DR, Silva AA Jr, Oliveira AG, Pizzolitto AC, Lavinsky D, Skaf M, Souza-Filho AA, Höfling-Lima AL, Nguyen QD, Kuppermann BD, Herrero-Vanrell R, Belfort R Jr; Brazilian Ocular Pharmacology and Pharmaceutical Technology Research Group. Paganelli F, et al. Among authors: lavinsky d. Expert Opin Drug Deliv. 2010 Aug;7(8):955-65. doi: 10.1517/17425247.2010.498817. Expert Opin Drug Deliv. 2010. PMID: 20645672 Review.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
63 results